Latest Interest Rates News

Waterco Limited reported a modest 4% revenue increase for FY25 but saw net profit fall sharply by 31%, weighed down by restructuring and foreign exchange losses. The company maintains its dividend and eyes growth through innovation and regional expansion.

Dexus has announced its 18.0 cents per security distribution for the first half of 2025, alongside robust full-year results that highlight a resilient portfolio and disciplined capital management. The company signals confidence with a steady outlook despite ongoing economic uncertainty.

Waypoint REIT delivered stable first-half earnings with a 4.7% rise in net tangible assets per security and increased its FY25 distributable earnings guidance, supported by ongoing asset sales and Viva Energy’s OTR conversions.

Waypoint REIT reported steady distributable earnings for the first half of 2025 alongside a significant rise in statutory net profit, while extending debt facilities and launching a $50 million buyback program.

Waypoint REIT reported steady distributable earnings of $55.6 million for the first half of 2025, supported by robust property valuations and disciplined capital management. Despite flat earnings, statutory net profit surged nearly 47%, reflecting significant valuation gains.

Bapcor Limited reported a modest revenue decline and an 8.4% drop in pro-forma NPAT for FY25 amid significant business simplification and strategic initiatives aimed at sustainable growth.

NobleOak Life Limited reported a robust 22% increase in underlying net profit after tax for FY25, driven by strong premium growth and expanding market share. Despite a statutory profit dip due to one-off costs, the insurer plans to reinvest cash flows to fuel future growth and transition to a Life Company structure.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Experience Co Limited reports a robust FY25 with revenue growth and a significant jump in earnings, driven by a tourism rebound in Australia and New Zealand.

Experience Co Limited reported a 6% increase in revenue to $134.3 million for FY25, alongside a 34% rise in underlying EBITDA to $19.3 million, marking its best financial performance since FY19. The company declared a fully franked dividend and initiated a 10% on-market share buy-back.

Glennon Small Companies Limited reported a robust FY25 with a 232.75% jump in net profit and declared final dividends, while strategically resetting its preference shares amid evolving small-cap market dynamics.